INmune Bio Corp (INMB): Broker Consensus Forecast
This daily price chart for INmune Bio, Inc. (INMB) reflects the asset's dynamics, with a value of 6.99. The US biotech firm is betting on innovative immune correction to combat Alzheimer's. Despite the risk of trial failures and the need for R&D capital, the company relies on a modern laboratory base and the readiness of partners for mass drug production.
Analytical breakdowns for INmune Bio Corp (INMB)
- price and consensus price forecast:
- stock exchange capitalization data:
- business book valuation details:
- issuer credit burden and liquidity indicators:
Aggregate Debt to Equity INmune Bio, Inc.|INMB - Long-Term Debt to Capital|Ratio of Short-Term Indebtedness to Capital INmune Bio Corporation|INMB - Company Aggregate Debts|Debts to Book Capitalization INmune Bio Corp|INMB - Company Long-Term Debt|Company Short-Term Loans and Borrowings INmune Bio|Quick Liquidity Indicator inmunebio.com
- business earnings and investment ratios data:
INMB - Net Profit|Projected Future Earnings INmune Bio, Inc.|INMB - Price to Earnings Ratio|Future Price to Earnings Multiple INmune Bio Inc|INMB - PEG Multiple|Total Company Value to Operating Income Before Depreciation Ratio INmune Bio Corp|INMB - Profit before payment of interest, taxes and amortization|Net earnings per share for the last 12 months INmune Bio|INMB - Earnings per share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months inmunebio.com|INMB - Net earnings per share growth this year|Earnings growth forecast for next year INmune Bio, Inc.
General company analysis:INMB inmunebio.com
This indicator represents the aggregated average target price from leading investment banks, reflecting the asset's fundamental growth potential under current macroeconomic conditions. Analyzing the market's average target price on the GURU.Markets platform allows for an assessment of expert expectations regarding the success of XPro1595 trials and the prospects for combating neuroinflammation, which is critical for valuing the INmune Bio, Inc. (INMB) biotech pipeline.
Competitors of INmune Bio, Inc.
Analyst Median Target argenx.com|Price Target Chart BioNTech BNTX|ABVX: Broker Consensus Forecast|ADMA - Price Target Chart|Protagonist Corp (PTGX) - Consensus Target|IMVT: Analyst Consensus Forecast|KNSA (kiniksa.com) - Price Target Chart|Price Target Chart Grifols|Adaptive Biotech - Forecast Levels Chart|Analyst Consensus Forecast CLDX|AUPH (Aurinia Corp) - Fair Value Consensus|Analyst Consensus Forecast BCRX (BioCryst)|Analyst Consensus Forecast veratx.com VERA|DNTH - Price Target Chart|Fair Value Consensus PHVS (Pharvaris NV)|AbCellera (ABCL) - Price Target Chart|Consensus Target Tourmaline|PGEN (Precigen, Inc.) - Analyst Consensus Forecast|Analyst Consensus Forecast pharming.com|Consensus Target NKTR (Nektar Therapeutics Inc.)|UPB (Upstream Bio, Inc.) - Fair Value Consensus|Analyst Consensus Forecast ZBIO (Zenas Biopharma, Inc.)|Analyst Median Target Immunome Bio (IMNM)|GOSS - Price Target Chart|kalvista.com (KALV) - Consensus Target|Septerna (SEPN) - Price Target Chart|Consensus Target Pieris Pharma|Consensus Target SVRA|Analyst Consensus Forecast Rigel Corp|Price Target Chart AnaptysBio, Inc. (ANAB)|astriatx.com - Broker Consensus Forecast|Analyst Consensus Forecast ENGN (enGene)|rapt.com (RAPT) - Average Forecast Price|Aerovate - Analyst Consensus Forecast|Analyst Median Target Aclaris Therapeutics, Inc ACRS|Kyverna Therapeutics (KYTX) - Price Target Chart|Broker Consensus Forecast TLSA|Price Target Chart Cabaletta Bio|Consensus Target Ventyx Biosciences Inc. (VTYX)|Consensus Target THTX (Theratechnologies Inc)|Analyst Consensus Forecast Avalo Therapeutics Inc (AVTX)|Price Target Chart Eledon Pharmaceuticals ELDN|AGEN: Broker Consensus Forecast|Climb Bio - Analyst Consensus Forecast|Average Forecast Price zurabio.com|ATYR (aTyr) - Consensus Target|Adagene Inc. - Fair Value Consensus|IMA (ImageneBio) - Analyst Consensus Forecast|Price Target Chart STTK|Analyst Consensus Forecast EQ|Analyst Median Target connectbiopharm.com|Price Target Chart Immunic IMUX|Atara Biotherapeutics, Inc. (ATRA) - Average Forecast Price|IFRX: Consensus Target|Fair Value Consensus XFOR (x4pharma.com)|ACET: Analyst Consensus Forecast|CELU - Analyst Median Target|Price Target Chart Barinthus Bio|Broker Consensus Forecast KZR (Kezar Life Sciences Inc)|Analyst Consensus Forecast SABS|Consensus Target akaritx.com AKTX|Enlivex Therapeutics Ltd. - Consensus Target|Analyst Median Target Q32 Bio Inc (QTTB)|GeoVax Labs Inc - Analyst Consensus Forecast|Analyst Median Target Edesa Biotech Corp EDSA|iBio, Inc. (IBIO) - Price Target Chart|Broker Consensus Forecast CARM|Price Target Chart XTL Biopharmaceuticals Ltd.|Consensus Target Bolt Bio (BOLT)|Analyst Consensus Forecast HCWB|Price Target Chart APVO (aptevotherapeutics.com)|Price Target Chart AIM ImmunoTech AIM|ADTX (Aditxt Inc.) - Forecast Levels Chart|GRI Bio - Analyst Consensus Forecast|Fair Value Consensus XRTX (XORTX Therapeutics Inc)|HIND: Analyst Consensus Forecast|Revelation Biosciences Corp (REVB) - Analyst Consensus Forecast|Price Target Chart Indaptus Therapeutics|SCNI: Fair Value Consensus|Price Target Chart CalciMedica, Inc. (CALI)|Consensus Target affimed.com AFMD|Analyst Consensus Forecast ALLK (Allakos)|Analyst Consensus Forecast HOOKIPA Pharma, Inc. HOOK|IGMS: Consensus Target|Fair Value Consensus ITOS (iteostherapeutics.com)|OCEA: Analyst Consensus Forecast|TCBP - Analyst Median Target|Price Target Chart Third Harmonic Bio, Inc
